Por favor, use este identificador para citar o enlazar este ítem:
http://repositorio.pediatria.gob.mx:8180/handle/20.500.12103/2100| Título : | Baclofen in the therapeutic of sequele of traumatic brain injury: spasticity |
| Creador: | Pérez Arredondo Adán |
| Nivel de acceso: | Open access |
| Palabras clave : | Baclofeno - uso terapéutico Traumatismos Encefálicos - clasificación Traumatismos Encefálicos - complicaciones Traumatismos Encefálicos - quimoterapia Progresión de la Enfermedad Humanos Relajantes Musculares Centrales - uso terapéutico Espasticidad Muscular - quimioterapía Espasticidad Muscular - etiología Baclofen - therapeutic use Brain Injuries, Traumatic -classification Brain Injuries, Traumatic -complications Brain Injuries, Traumatic - drug therapy Disease Progression Humans Muscle Relaxants, Central - therapeutic use Muscle Spasticity - drug therapy Muscle Spasticity - etiology Baclofeno Espasticidad Traumatismos Encefálicos Baclofen spasticity traumatic brain injury |
| Descripción : | Traumatic brain injury (TBI) is an alteration in brain function, caused by an external force, which may be a hit on the skull, rapid acceleration or deceleration, penetration of an object, or shock waves from an explosion. Traumatic brain injury is a major cause of morbidity and mortality worldwide, with a high prevalence rate in pediatric patients, in which treatment options are still limited, not available at present neuroprotective drugs. Although the therapeutic management of these patients is varied and dependent on the severity of the injury, general techniques of drug types are handled, as well as physical and surgical. Baclofen is a muscle relaxant used to treat spasticity and improve mobility in patients with spinal cord injuries, relieving pain and muscle stiffness. Pharmacological support with baclofen is contradictory, because disruption of its oral administration may cause increased muscle tone syndrome and muscle spasm, prolonged seizures, hyperthermia, dysesthesia, hallucinations, or even multisystem organ failure. Combined treatments must consider the pathophysiology of broader alterations than only excitation/inhibition context, allowing the patient's reintegration with the greatest functionality. Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved. |
| Colaborador(es) u otros Autores: | Cázares-Ramírez Eduardo Paul Carrillo-Mora Paul Martínez-Vargas Marina Cárdenas-Rodríguez Noemí Coballase-Urrutia Elvia Alemón-Medina Radamés Sampieri Aristides Navarro Luz Carmona-Aparicio Liliana |
| Fecha de publicación : | 2016 |
| Tipo de publicación: | Revisión |
| Formato: | |
| Identificador del Recurso : | 10.1097/WNF.0000000000000179 |
| Fuente: | Clinical Neuropharmacology 39(6):311 - 319 |
| URI : | http://repositorio.pediatria.gob.mx:8180/handle/20.500.12103/2100 |
| Idioma: | eng |
| Aparece en las colecciones: | Artículos |
Ficheros en este ítem:
No hay ficheros asociados a este ítem.
Los ítems de DSpace están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.